Kairos Pharma, Ltd. (KAPA) Stock Price
KAPAStock
$0.25−80.34%52W
Market Cap$5.88M
P/E—
PEG Ratio—
Div yield—
Beta3.13
KAPA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-70.98%
Price vs S&P 500 (4W)-27.73%
VGM Score8.33
KAPA Earnings Surprise History
Q2 25-0.08est. -0.05
Q3 25-0.07est. -0.07
Q4 25-0.07est. 0.03
Q1 26-0.08est. -0.07
KAPA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.11
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KAPAKairos Pharma, Ltd. | — | — | F | $0.25 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharmaceutical company developing cancer immunotherapies designed to overcome immune suppression and drug resistance. Its pipeline includes antibody and small molecule candidates targeting prostate cancer, lung cancer, breast cancer, and glioblastoma.